SDF-1/CXCR4 axis enhances the immunomodulation of human endometrial regenerative cells in alleviating experimental colitis

Stem Cell Res Ther. 2019 Jul 8;10(1):204. doi: 10.1186/s13287-019-1298-6.

Abstract

Endometrial regenerative cells (ERCs) are a new type of mesenchymal-like stromal cells, and their therapeutic potential has been tested in a variety of disease models. SDF-1/CXCR4 axis plays a chemotaxis role in stem/stromal cell migration. The aim of the present study was to investigate the role of SDF-1/CXCR4 axis in the immunomodulation of ERCs on the experimental colitis. The immunomodulation of ERCs in the presence or absence of pretreatment of SDF-1 or AMD3100 was examined in both in vitro cell culture system and dextran sulphate sodium-induced colitis in mice. The results showed that SDF-1 increased the expression of CXCR4 on the surface of ERCs. As compared with normal ERCs, the SDF-1-treated, CXCR4 high-expressing ERCs more significantly suppressed dendritic cell population as well as stimulated both type 2 macrophages and regulatory T cells in vitro and in vivo. Meanwhile, SDF-1-pretreated ERCs increased the generation of anti-inflammatory factors (e.g., IL-4, IL-10) and decreased the pro-inflammatory factors (e.g., IL-6, TNF-α). In addition, SDF-1-pretreated CM-Dil-labeled ERCs were found to engraft to injured colon. Our results may suggest that an SDF-1-induced high level of CXCR4 expression enhances the immunomodulation of ERCs in alleviating experimental colitis in mice.

Keywords: C-X-C chemokine receptor type 4; Endometrial regenerative cells; Immunoregulation; Stromal cell-derived factor-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzylamines
  • Cells, Cultured
  • Chemokine CXCL12 / pharmacology*
  • Chemokine CXCL12 / therapeutic use
  • Colitis / chemically induced
  • Colitis / drug therapy
  • Colitis / metabolism*
  • Cyclams
  • Endometrium / cytology*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Flow Cytometry
  • Heterocyclic Compounds / pharmacology*
  • Heterocyclic Compounds / therapeutic use
  • Humans
  • Male
  • Mice, Inbred BALB C
  • Receptors, CXCR4 / metabolism*
  • Spleen / cytology
  • T-Lymphocytes, Regulatory / drug effects
  • T-Lymphocytes, Regulatory / metabolism

Substances

  • Benzylamines
  • CXCR4 protein, human
  • Chemokine CXCL12
  • Cyclams
  • Heterocyclic Compounds
  • Receptors, CXCR4
  • plerixafor